ascendis pharma glp-1 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 1 Support helps support appetite control Novo puts $285m into monthly

The facts of each case differ from one to the next

How Long Side Effects May Last There is no single answer, but common patterns include: mild nausea and fullness improving after a few weeks bloating and constipation improving with food and water changes burping and heartburn improving when you slow down eating Some people have small waves of symptoms that return when they move up to a higher dose

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management, with some now also licensed for weight management

Mood Changes Mood swings and depression have been reported in some cases

It covers why semaglutide and tirzepatide work on different timelines, why appetite suppression arrives before weight loss does, why your neighbor lost ten pounds in month one while you lost three, and what the clinical trial data actually says about realistic expectations